Several brokerages have updated their recommendations and price targets on shares of Coherus Biosciences (NASDAQ: CHRS) in the last few weeks:

  • 9/11/2018 – Coherus Biosciences was downgraded by analysts at BidaskClub from a “buy” rating to a “hold” rating.
  • 9/7/2018 – Coherus Biosciences was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “Coherus Biosciences, Inc. is a biologics platform company developing biosimilar therapeutics. Its clinical stage pipeline consists of CHS-0214 in two Phase III clinical trials for the treatment of rheumatoid arthritis and psoriasis; CHS-1420 that has completed a Phase I study to treat psoriasis or rheumatoid arthritis; and CHS-1701 which has completed a Phase I study for the treatment of breast cancer patients. Coherus Biosciences, Inc. is headquartered in Redwood City, California. “
  • 8/28/2018 – Coherus Biosciences is now covered by analysts at HC Wainwright. They set a “buy” rating and a $28.00 price target on the stock.
  • 8/24/2018 – Coherus Biosciences was upgraded by analysts at BidaskClub from a “hold” rating to a “buy” rating.
  • 8/13/2018 – Coherus Biosciences was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “sell” rating. According to Zacks, “Coherus Biosciences, Inc. is a biologics platform company developing biosimilar therapeutics. Its clinical stage pipeline consists of CHS-0214 in two Phase III clinical trials for the treatment of rheumatoid arthritis and psoriasis; CHS-1420 that has completed a Phase I study to treat psoriasis or rheumatoid arthritis; and CHS-1701 which has completed a Phase I study for the treatment of breast cancer patients. Coherus Biosciences, Inc. is headquartered in Redwood City, California. “
  • 8/2/2018 – Coherus Biosciences was upgraded by analysts at ValuEngine from a “buy” rating to a “strong-buy” rating.
  • 7/19/2018 – Coherus Biosciences was upgraded by analysts at ValuEngine from a “hold” rating to a “buy” rating.

CHRS traded up $0.35 during trading on Wednesday, reaching $17.90. 21,748 shares of the stock traded hands, compared to its average volume of 695,026. Coherus Biosciences Inc has a 12 month low of $8.05 and a 12 month high of $20.66. The stock has a market capitalization of $1.28 billion, a P/E ratio of -4.00 and a beta of 3.65. The company has a current ratio of 7.79, a quick ratio of 7.79 and a debt-to-equity ratio of 1.66.

Coherus Biosciences (NASDAQ:CHRS) last announced its quarterly earnings data on Wednesday, August 8th. The biotechnology company reported ($0.68) earnings per share for the quarter, missing the consensus estimate of ($0.64) by ($0.04). research analysts predict that Coherus Biosciences Inc will post -3.03 EPS for the current fiscal year.

In other news, CFO Jean-Frederic Viret sold 9,291 shares of the company’s stock in a transaction dated Monday, July 23rd. The shares were sold at an average price of $18.56, for a total transaction of $172,440.96. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, insider Barbara K. Finck sold 1,760 shares of the company’s stock in a transaction dated Tuesday, July 10th. The shares were sold at an average price of $15.01, for a total transaction of $26,417.60. Following the transaction, the insider now owns 37,543 shares in the company, valued at approximately $563,520.43. The disclosure for this sale can be found here. Insiders have sold 41,331 shares of company stock worth $803,935 in the last quarter. Company insiders own 19.57% of the company’s stock.

Several hedge funds and other institutional investors have recently made changes to their positions in the company. BlackRock Inc. raised its holdings in shares of Coherus Biosciences by 24.3% during the second quarter. BlackRock Inc. now owns 4,144,082 shares of the biotechnology company’s stock valued at $58,018,000 after purchasing an additional 810,358 shares during the period. Sofinnova Ventures Inc acquired a new stake in shares of Coherus Biosciences in the 1st quarter worth about $31,970,000. JPMorgan Chase & Co. raised its holdings in shares of Coherus Biosciences by 7.5% in the 1st quarter. JPMorgan Chase & Co. now owns 2,045,068 shares of the biotechnology company’s stock worth $22,598,000 after acquiring an additional 143,074 shares during the last quarter. Orbimed Advisors LLC raised its holdings in shares of Coherus Biosciences by 0.9% in the 2nd quarter. Orbimed Advisors LLC now owns 1,480,482 shares of the biotechnology company’s stock worth $20,727,000 after acquiring an additional 13,682 shares during the last quarter. Finally, Rock Springs Capital Management LP raised its holdings in shares of Coherus Biosciences by 10.4% in the 1st quarter. Rock Springs Capital Management LP now owns 695,000 shares of the biotechnology company’s stock worth $7,680,000 after acquiring an additional 65,500 shares during the last quarter. Hedge funds and other institutional investors own 91.32% of the company’s stock.

Coherus BioSciences, Inc, a biosimilar company, develops and commercializes various therapeutic products worldwide. The company engages in the development of late-stage clinical products, including CHS-1701 pegfilgrastim biosimilar, a granulocyte colony-stimulating factor product candidate; CHS-1420 adalimumab biosimilar, an anti-tumor necrosis factor product candidate; and CHS-0214, an etanercept biosimilar for rheumatoid arthritis and psoriasis.

Featured Story: Are Wall Street analysts’ stock ratings worth following?

Receive News & Ratings for Coherus Biosciences Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Coherus Biosciences Inc and related companies with MarketBeat.com's FREE daily email newsletter.